NovaRx Corporation (Novarx)

Oncology Corporate Profile

HQ Location

6828 Nancy Ridge Drive, Suite 100
San Diego, CA 92121

Company Description

NovaRx Corporation is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel cell-based therapeutic vaccines for the treatment of cancer. The company was founded in San Diego, California in May 1997 in order to commercialize the award-winning research of Dr. Habib Fakhrai and his associates at the Sidney Kimmel Cancer Center in San Diego and at the UCLA School of Medicine in Los Angeles. The proprietary core technology has been exclusively licensed to NovaRx on a worldwide basis.

Website: http://www.novarx.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Lucanix® / belagenpumatucel-LimmunotherapyNon Small Cell Lung Cancer (NSCLC)III
Glionix®immunotherapyGliomaI

View additional information on product candidates here »

Source: http://www.novarx.com/

Recent News Headlines

NovaRx Announces Results of Lucanix® Phase III Therapeutic Vaccine Trial for Post-frontline Maintenance Therapy in Non-small Cell Lung Cancer to Be Presented at ESMO

9/25/2013 05:05 pm

(San Francisco Business Times) Sep 25, 2013 - NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix® (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the ESMO 2013 annual meeting in Amsterdam on 28 September 2013 as part of "Presidential Session I: Best and Late Breaking Abstracts."

NovaRx Announces Results of Lucanix® Phase III Therapeutic Vaccine Trial for Post-frontline Maintenance Therapy in Non-small Cell Lung Cancer to Be Presented at ESMO

9/25/2013 12:00 pm

(San Francisco Business Times) Sep 25, 2013 - NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix® (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the ESMO 2013 annual meeting in Amsterdam on 28 September 2013 as part of "Presidential Session I: Best and Late Breaking Abstracts."

NovaRx Completes Enrollment in Lucanix Pivitol Phase III Therapeutic Vaccine Trial for Post Frontline Maintenace Therapy in Non Small Cell Lung Cancer

6/20/2012 04:57 pm

(BizJournals) June 20, 2012 - First interim analysis for NSCLC trial in third quarter 2012 - NovaRx Corporation announced that it has recently completed the planned enrollment in its Phase III clinical trial of Lucanix® (belagenpumatucel-L). Lucanix is an investigational whole tumor cell vaccine for the treatment of non-small cell lung cancer.

NovaRx Completes Enrollment in Lucanix Pivitol Phase III Therapeutic Vaccine Trial for Post Frontline Maintenace Therapy in Non Small Cell Lung Cancer

6/20/2012 11:05 am

(BizJournals) June 20, 2012 - First interim analysis for NSCLC trial in third quarter 2012 - NovaRx Corporation announced that it has recently completed the planned enrollment in its Phase III clinical trial of Lucanix® (belagenpumatucel-L). Lucanix is an investigational whole tumor cell vaccine for the treatment of non-small cell lung cancer.

UAB's Comprehensive Cancer Center Gets $15 Million Federal Grant to Reduce Costs of Care

6/18/2012 12:03 pm

(Birmingham News blog) June 16, 2012 - The University of Alabama at Birmingham's Comprehensive Cancer Center has received a three-year, $15 million federal grant to help find ways to reduce cancer care costs.

Overall Health May Be Key to Beating Breast Cancer

4/6/2011 01:00 pm

(U.S. News & World Report) Apr 6, 2011 - Poor overall health seems to be associated with worse outcomes for breast cancer survivors, according to the results of a new study.